Artificial Intelligence–Driven Biomarker Discovery in Genitourinary Oncology: An Integrative Review
Medical Research Archives · 2026
DOI: 10.18103/mra.2026.0777 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Research Archives, 2026. Verfasst von Alcides Chaux und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction
Genitourinary malignancies — prostate, urothelial/bladder, renal cell, penile, and testicular germ cell tumors — account for a substantial share of the global cancer burden. Artificial intelligence (AI) and machine learning (ML) methods, applied to digital pathology, radiological imaging, and multi-omics data, have rapidly expanded as tools for biomarker discovery, but no integrative synthesis has mapped what has been produced across tumor sites, data modalities, and clinical purposes, or how mature this evidence is for clinical translation. Materials and methods: We conducted an integrative review (Whittemore and Knafl framework) of studies using AI/ML to discover or prioritize a biomarker in genitourinary neoplasms. MEDLINE and Europe PMC were searched independently by tumor site (2026-09-09), followed by a supplementary citation-tracking search (2026-09-23). Two reviewers independently screened titles/abstracts and full texts, with consensus resolution. Studies were appraised with MMAT 2018, supplemented by PROBAST-2019 and TRIPOD+AI-informed indicators for prediction models, and extracted onto a standardized form. Synthesis was narrative, stratified by tumor site and data modality; no meta-analysis was planned given outcome heterogeneity.
Results
Of 697 unique database records, 507 studies met eligibility (400 from database searching, 107 from citation tracking). Kidney (181), prostate (174), and bladder/urothelial (133) tumors dominated the corpus, while testicular (13) and penile (1) cancers were markedly underrepresented. Radiological imaging (217) and transcriptomics (164) were the leading modalities; prognosis (258) and diagnosis (187) the leading purposes. External validation was present in 258 of 507 studies, but none demonstrated clinical utility in the sense of measured decision or outcome impact, code was available in 21 of 507, and an AI/ML reporting guideline was declared in only 15 of 507. PROBAST-2019 flagged elevated risk-of-bias concerns in 463 of 505 appraised studies, an instrument whose applicability to high-dimensional discovery designs is limited.
Conclusions
AI/ML-driven biomarker discovery in genitourinary oncology has produced an extensive descriptive map of prognostic and diagnostic signatures, concentrated in imaging and transcriptomic modalities for kidney, prostate, and bladder cancer, but translational readiness remains narrow: external validation is inconsistent, code and data sharing are rare, and reporting-guideline adherence is low. Penile and testicular cancers remain substantial evidence gaps.
Zitieren
APA
Chaux, A., & Britos, P. (2026). Artificial Intelligence–Driven Biomarker Discovery in Genitourinary Oncology: An Integrative Review. Medical Research Archives. https://doi.org/10.18103/mra.2026.0777
Vancouver
Chaux A, Britos P. Artificial Intelligence–Driven Biomarker Discovery in Genitourinary Oncology: An Integrative Review. Medical Research Archives. 2026. doi:10.18103/mra.2026.0777
BibTeX
@article{Chaux2026,
author = {Chaux, Alcides and Britos, Paola},
title = {Artificial Intelligence–Driven Biomarker Discovery in Genitourinary Oncology: An Integrative Review},
journal = {Medical Research Archives},
year = {2026},
doi = {10.18103/mra.2026.0777}
}
EUVIMED